XOMA-213 is under clinical development by XOMA and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect XOMA-213’s likelihood of approval (LoA) and phase transition for Hyperprolactinaemia took place on 18 Dec 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their XOMA-213 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

XOMA-213 overview

XOMA-213 (LFA-102) is under development for the treatment of various hyperprolactinemias. The therapeutic candidate is administered through intravenous route. The therapeutic candidate is a anti-prolactin receptor humanized monoclonal antibody of the IgG1 kappa subtype. It was also under development for the treatment of prolactin receptor positive castration-resistant prostate cancer, metastatic breast cancer and uterine leiomyoma.

XOMA overview

XOMA, formerly XOMA Ltd, is a biopharmaceutical company. It develops antibody-based therapeutics. Its lead product, Gevokizumab is a monoclonal antibody used for the treatment of a wide variety of inflammatory diseases and other diseases. Its other pipeline products include RZ358, XMetA, X213 (formerly LFA 102) and PTH1R. XOMA X358 is a human negative allosteric modulating insulin receptor antibody; X213 is an allosteric inhibitor of prolactin action. XOMA has a developed proprietary antibody platform, optimization and development technologies, comprising ADAPT, ModulX and OptimX. It operates through its subsidiaries in Bermuda, Ireland, and the US. XOMA is headquartered in Berkeley, California, the US.

Quick View XOMA-213 LOA Data

Report Segments
  • Innovator
Drug Name
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Hormonal Disorders
  • Non Malignant Disorders
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.